Skip to main content

Rosetta Genomics BRAF Mutation Assay

Rosetta Genomics has launched a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. The test uses competitive allele-specific TaqMan (CAST) PCR technology, which can detect as little as 0.5 percent mutated DNA in a large, normal DNA sample. BRAF mutations occur in up to 50 percent of malignant melanomas, and several US Food and Drug Administration-approved BRAF inhibitor therapies have been introduced to the market for use in patients with late-stage metastatic melanoma, Rosetta noted.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.